Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma
Primary Purpose
Pediatric Glaucoma
Status
Unknown status
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
FP7 Ahmed Glaucoma Drainage Implant
FP8 Glaucoma Drainage Implant
Sponsored by
About this trial
This is an interventional treatment trial for Pediatric Glaucoma focused on measuring Glaucoma, Pediatric, Ahmed, Congenital, FP7, FP8
Eligibility Criteria
Inclusion Criteria:
- Diagnostic of Pediatric Glaucoma with indication of Ahmed Glaucoma Valve implantation
- Age from 0 to 10 years old
Exclusion Criteria:
- Children older then 10 years old
Sites / Locations
- Federal University of São Paulo - Ophthalmology DepartmentRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
FP7 implant
FP8 implant
Arm Description
Outcomes
Primary Outcome Measures
Position of the drainage implant plate
The primary endpoint is to evaluate the position of the drainage implant plate and if the plate is positioned at a distance ≥ 8 mm from the corneal limbus after 1 year of surgery, considered successful. If the plate is positioned at a distance <8 mm from the corneal limbus, we have a failure.
Secondary Outcome Measures
As a secondary outcome, we evaluate the variation in IOP preoperative and postoperative.
We will use as a criterion of success an IOP ≤ 21 mm Hg and> 5 mmHg and a 30% reduction of preoperative IOP. If the patient meets these criteria, without the use of eyedrop, classified as complete success. If the use of eyedrop is necessary to meet the criteria, a qualified success will be defined.
For failure criterion is assumed: IOP ≤ 5 mmHg or > 21 mm Hg, even with the use of eye drops, need for further surgery, and / or loss of light perception.
Full Information
NCT ID
NCT01494974
First Posted
December 15, 2011
Last Updated
April 6, 2014
Sponsor
Federal University of São Paulo
1. Study Identification
Unique Protocol Identification Number
NCT01494974
Brief Title
Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma
Official Title
Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma: a Randomized Clinical Trial.
Study Type
Interventional
2. Study Status
Record Verification Date
April 2014
Overall Recruitment Status
Unknown status
Study Start Date
December 2011 (undefined)
Primary Completion Date
December 2015 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Federal University of São Paulo
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to compare the success rates and complications of two models of Ahmed glaucoma implants (FP7 and FP8) in patients with pediatric glaucoma.
Detailed Description
INTRODUCTION
The drainage implants have become an important alternative in the treatment of pediatric glaucoma refractory to angular and filtration surgery or medical therapy (1). Such implants drain the aqueous humor from the anterior chamber of the eye to a plate positioned above the sclera, between the rectus muscles. The aqueous humor goes through the pseudocyst that forms around the plate by passive diffusion and is drained by the venous capillaries and lymphatic system.
The Ahmed drainage implant (New World Medical, Inc., Rancho Cucamonga, CA, USA) is a device with flow restrictors, which decreases the incidence of postoperative complications such as hypotony (2-3). It is made of silicone and comes in two sizes. The FP7 model has a surface of 184 mm2, 13mm wide and 16mm long. The FP8 model presents 96mm2 surface, 9.6 mm wide and 10mm long.
Studies in animals and adult humans suggest that the surface area of the implant plate is directly related to the amount of aqueous fluid drained through the same (4-7). In contrast, a very large implant can result in the extrusion of the same, uncontrolled intraocular pressure, corneal injury by endothelial touch, patient discomfort and ocular motility problems. The use of pediatric size implants in small eyes can avoid such complications. A high rate (34.8%) of anterior plate of the tubes in children under 2 years of age has been reported (8-9). On the other hand, the use of pediatric implante may affect the control of intraocular pressure (IOP) due to reduced drainage area (10), especially in eyes with increasing axial diameter, a result of increased eye pressure that happens in children with glaucoma. However, there is no study in the literature comparing different sizes of drainage implants in pediatric patients.
A study to compare the success rates and complications between FP7 and FP8 models is essential in order to standardize a conduct in choosing the type of implant. Currently, the choice of the drainage implant model to be used in every child lies on the free choice and personal preference of the surgeon. There is no standard procedure, based on scientific evidence for this choice.
OBJECTIVES
Compare the success rates and complications of two models of Ahmed drainage implant (FP7 and FP8) in patients with pediatric glaucoma.
MATERIALS AND METHODS
This clinical trial is a prospective, randomized, masked to the evaluator to be held at the Department of Ophthalmology, Federal University of Sao Paulo.
Will be included children between 0 and 10 years of age with glaucoma and surgical indication for glaucoma drainage implant. Surgical indication for implantation of Ahmed drainage occurs in some situations: 1) children with primary congenital glaucoma that undergone angular surgery (goniotomy and / or trabeculotomy) who did not respond satisfactorily to surgery, 2) children with glaucoma secondary to aphakia who have the primary indication for implantation of Ahmed drainage, 3) children with glaucoma secondary to other eye disorders where medical treatment is not satisfactory.
A term of consent will be obtained from parents or legal guardians of the child, in which all the risks inherent to the surgical procedure will be clarified. Such risks are proper to antiglaucomatous surgery are:
Early: hypotony, hyphema, tube endothelial touch, choroidal detachment, leakage of aqueous, vitreous hemorrhage, retinal detachment, loss of light perception
late: uncontrolled intraocular pressure, persistent hypotony, scleral patch resorption, extrusion of the tube, retinal detachment, loss of light perception (11-18).
Considering that the selected patient has already the surgical indication for Ahmed drainage implant, the inclusion of this child in the study does not bring additional risks or discomforts to the same.
The model of the drainage implant will be chosen through allocation from a computer-generated random table.
Children enrolled in the study will be divided into two groups (one group will receive the model FP7 and another group will receive the model FP8) with the number of 20 participants in each group, totaling 40 children.
The surgeries will be performed by experienced surgeons from Glaucoma Sector from Department of Ophthalmology, Federal University of Sao Paulo.
The plate of the Ahmed drainage implant will be placed in one of the quadrants selected from the extraocular muscles between 8 and 10 mm away from the corneal limbus. The tube will have its distal portion inserted 2-3mm into the anterior chamber of the eye in the iris plane. The exposed portion of the tube is covered with donor sclera.
The children included in the study will be examined before surgery, which will be measured your visual acuity, biomicroscopy, IOP, Retinography and axial length of the eye. Immediately after surgery, with a compass we will measure the distance between the plate of drainage implant and corneal limbus.
Children will be examined again after 6 months and 1 year of surgery. We will perform the measurement of visual acuity, biomicroscopy, IOP, Retinography, axial length and measurement of the distance from the plate of the implant and corneal limbus. Post-operative examinations will be performed under narcosis, in hospitals (when it is impossible to take measures in an outpatient setting due to lack of cooperation of the child), by a doctor from congenital glaucoma sector who were not involved in the surgical procedure. The examination under narcosis involves risk to the child, which include cough, nausea, vomiting, laryngospasm, bronchospasm, apnea, bradycardia, tachycardia, hypertension, anxiety (19-21).
Two types of outcome will be considered in this study. The primary endpoint is to evaluate the position of the drainage implant plate and if the plate is positioned at a distance ≥ 8 mm from the corneal limbus after 1 year of surgery, considered successful. If the dish drain implant is positioned at a distance <8 mm from the corneal limbus, we have a failure.
As a secondary outcome, we evaluate the variation in IOP preoperative and postoperative. We will use as a criterion of success an IOP ≤ 21 mm Hg and> 5 mmHg and a 30% reduction of preoperative IOP. If the patient meets these criteria, without the use of eyedrop, classified as complete success. If the use of eyedrop is necessary to meet the criteria, a qualified success will be defined.
For failure criterion is assumed: IOP ≤ 5 mmHg or > 21 mm Hg, even with the use of eye drops, need for further surgery, and / or loss of light perception.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pediatric Glaucoma
Keywords
Glaucoma, Pediatric, Ahmed, Congenital, FP7, FP8
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
FP7 implant
Arm Type
Active Comparator
Arm Title
FP8 implant
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
FP7 Ahmed Glaucoma Drainage Implant
Intervention Description
Ahmed Glaucoma Valve model FP7
Intervention Type
Device
Intervention Name(s)
FP8 Glaucoma Drainage Implant
Intervention Description
Ahmed Glaucoma Valve model FP8
Primary Outcome Measure Information:
Title
Position of the drainage implant plate
Description
The primary endpoint is to evaluate the position of the drainage implant plate and if the plate is positioned at a distance ≥ 8 mm from the corneal limbus after 1 year of surgery, considered successful. If the plate is positioned at a distance <8 mm from the corneal limbus, we have a failure.
Time Frame
After 1 year of surgery
Secondary Outcome Measure Information:
Title
As a secondary outcome, we evaluate the variation in IOP preoperative and postoperative.
Description
We will use as a criterion of success an IOP ≤ 21 mm Hg and> 5 mmHg and a 30% reduction of preoperative IOP. If the patient meets these criteria, without the use of eyedrop, classified as complete success. If the use of eyedrop is necessary to meet the criteria, a qualified success will be defined.
For failure criterion is assumed: IOP ≤ 5 mmHg or > 21 mm Hg, even with the use of eye drops, need for further surgery, and / or loss of light perception.
Time Frame
After 1 year of surgery
10. Eligibility
Sex
All
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnostic of Pediatric Glaucoma with indication of Ahmed Glaucoma Valve implantation
Age from 0 to 10 years old
Exclusion Criteria:
Children older then 10 years old
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Camila F Netto, MD
Phone
+55-1199177717
Email
milanetto@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Camila F Netto, MD
Organizational Affiliation
Assistant Doctor at Ophthalmology Department
Official's Role
Principal Investigator
Facility Information:
Facility Name
Federal University of São Paulo - Ophthalmology Department
City
São Paulo
ZIP/Postal Code
04023-062
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Camila F Netto, MD
Phone
+55-11-99177717
Email
milanetto@gmail.com
First Name & Middle Initial & Last Name & Degree
Camila F Netto, MD
12. IPD Sharing Statement
Learn more about this trial
Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma
We'll reach out to this number within 24 hrs